2026-04-18T00:16:38Zhttps://recercat.cat/oai/requestoai:recercat.cat:2445/1077532025-11-20T10:16:27Zcom_2072_1057col_2072_478809col_2072_478917
A budget impact analysis of Spiromax compared with Turbuhaler for the treatment of moderate to severe asthma: a potential improvement in the inhalation technique to strengthen medication adherence could represent savings for the Spanish Healthcare System and five Spanish regions
Darbà, Josep
Ramírez, Gabriela
García-Rivero, Juan L.
Mayoralas, Sagrario
Pascual, José Francisco
Roger, Albert
Vargas, Diego
Bijedic, Adi
Administració de medicaments
Asma
Malalties pulmonars obstructives cròniques
Tractament tèrmic
Economia de la salut
Administration of drugs
Asthma
Chronic obstructive pulmonary diseases
Heat treatment
Medical economics
To assess the economic impact of the introduction of DuoResp(®) Spiromax(®) by focusing on a potential improvement in the inhalation technique to strengthen medication adherence for the treatment of moderate to severe asthmatics in Spain and five Spanish regions including Andalusia, Catalonia, Galicia, Madrid, and Valencia. ...
2017-03-02T15:37:24Z
2017-03-02T15:37:24Z
2016-09
2017-03-02T15:37:24Z
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Reproducció del document publicat a: https://doi.org/10.2147/CEOR.S111453
Clinicoeconomics and Outcomes Research, 2016, vol. 8 , p. 435-444
https://doi.org/10.2147/CEOR.S111453
cc-by-nc (c) Darbà, Josep et al., 2016
http://creativecommons.org/licenses/by-nc/3.0/es
info:eu-repo/semantics/openAccess
Dove Medical Press
Articles publicats en revistes (Economia)